Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with chemotherapy helped reduce the risk of death in patients with a type of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept jumps after relacorilant plus nab-paclitaxel hits overall survival endpoint in phase III ROSELLA study in ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...

By Diana Novak Jones Jan 20 (Reuters) - In a victory for thousands of women suing Johnson & Johnson over claims that the ...

The investigational cortisol modulator relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian ...

Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.

Shares of Corcept Therapeutics jumped after a trial found its investigational drug helped reduce the risk of death in patients with a treatment-resistent form of ovarian cancer. Shares rose 14% to $41 ...

For women, ovarian cancer is one of the most feared of all diagnoses. Sneaking up silently, often with few symptoms, the ...

Eli Lilly and Co. has received the Federal Drug Administration’s breakthrough therapy designation for a drug in development ...

Women with certain genetic mutations are at extremely high risk of ovarian cancer. Now, some researchers are trying a new ...

Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.